Ridgeback's A$15m investment in Prima will be made in two parts:
On 05.14.15 Co. hands over %5 for approximately A$1.25m of Prima's issued shares which means that with today's outstanding shares of 40 million it would value the Co. at MC of $20M, but with the current crazy pump 40M x $2.50 = $100M !!!! So why wouldn't Prima sell shares on the market right now and solve all its' financing problems for years to come? Are they stupid or criminal pumpers are? Just asking ....ask yourself too!
I share your impatience and exasperation, while the Co. is definitely taking a dramatic turn to an aggressive growth, the stock remains badly broken, beloved "sell the news" game of the street. So sad and unfair.
****** In any event, the deal does seem like it will be accretive to earnings in the long run.*****
So what would you attribute the projected 5 fold increase in revenue to $10-$12M in 2015 vs $2.5M gross billings in whole 2014, to a sudden organic growth? Even in the best case scenario of an exceptional success of thyroid test scheduled for Q3 the revenue and other collaborative products such a jump would be hardly imaginable. So this purchase must be highly accretive even in the short run even after taking into account additional general expenses and other associated overhead. Just wonder what is the logic behind your bitter claim?